Valuation: Agenus Inc.

Market Cap 311M 269M 252M 231M 434M 29.64B 441M 2.95B 1.16B 14.86B 1.17B 1.14B 49.12B P/E 2026 *
8x
P/E 2027 * -116x
Enterprise Value 311M 269M 252M 231M 434M 29.64B 441M 2.95B 1.16B 14.86B 1.17B 1.14B 49.12B EV / Sales 2026 *
2.22x
EV / Sales 2027 * 2.27x
Free-Float
93.27%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agenus Inc.

1 day-7.08%
1 week-12.01%
Current month-7.20%
1 month+104.11%
3 months+78.92%
6 months+136.73%
Current year+121.66%
1 week 6.92
Extreme 6.92
8.85
1 month 3.1
Extreme 3.1
8.85
Current year 2.71
Extreme 2.71
8.85
1 year 2.71
Extreme 2.71
8.85
3 years 1.38
Extreme 1.38
32
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 73 30/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 31/10/2021
Director TitleAgeSince
Chairman 73 03/11/2010
Director/Board Member 68 07/03/2007
Director/Board Member 68 06/12/2006
Date Insider Type Main position Quantity % Market Cap.
10/07/26 Free

Chief Executive Officer

4,852 0.0117%
01/07/26 Free

Director

2,268 0.0054%
01/07/26 Free

Director

8,547 0.0205%
Change 5-day change 1-year change 3-year change Capi.($)
-7.08%-12.01%+46.22%-76.16% 335M
+0.99%+0.35%+4.91%+16.06% 48.7B
+3.71%+6.75%+459.45%+557.32% 42.05B
+2.70%+0.38%+34.49%+10.04% 38.26B
+5.60%+8.13%+16.67%+72.18% 37.5B
+2.21%+4.89%+17.24%+51.64% 31.44B
+2.23%+1.73% - - 16.47B
+0.97%+2.14%+37.25%+128.28% 16.33B
-0.11%+1.75%+8.05%+18.47% 13.98B
+0.75%+14.01%+77.94%+29.28% 12.68B
Average +1.20%+2.22%+78.02%+89.68% 25.77B
Weighted average by Cap. +2.50%+2.30%+98.52%+131.11%

Financials

2026 *2027 *
Net sales 140M 121M 113M 104M 196M 13.35B 199M 1.33B 522M 6.69B 527M 515M 22.13B 137M 119M 111M 102M 191M 13.06B 194M 1.3B 511M 6.55B 515M 504M 21.64B
Net income 46M 39.79M 37.16M 34.09M 64.11M 4.38B 65.13M 436M 171M 2.19B 173M 169M 7.25B -5.3M -4.58M -4.28M -3.93M -7.39M -504M -7.5M -50.23M -19.71M -253M -19.9M -19.47M -836M
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
07/08/26 US$6.960 -7.08% 1,133,190
06/08/26 US$7.490 -3.73% 2,455,450
05/08/26 US$7.780 -6.27% 1,457,472
04/08/26 US$8.300 +6.14% 2,017,318
03/08/26 US$7.820 +4.27% 1,654,258
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.960USD
Average target price
22.00USD
Spread / Average Target
+216.09%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock